Pinned Tweet
I’m excited to share that I’ll be joining the Department of Translational Neurosciences, College of Medicine–Phoenix at the University of Arizona as an Assistant Professor (Tenure-Track) in July 2026! #GPCR #Neuroscience #DrugDiscovery #StructuralBiology #UniversityOfArizon
In three patients with refractory epilepsy, hippocampal chemogenetic therapy plus low-dose clozapine was associated with a mean seizure-frequency reduction of 92.6%. Adverse events were grade 1 or 2. Full study results: nej.md/4Agtyhz

ALT Bar chart showing the frequency of monthly seizures for Patients 1, 2, and 3 before and after chemogenetic neuromodulation treatment. Orange bars indicate the number of seizures before treatment: Patient 1 has 4.5, Patient 2 has 4.0, and Patient 3 has 4.5. Purple bars indicate the number of seizures after treatment: Patient 1 has 0.5, Patient 2 has 0, and Patient 3 has 0.5. The vertical axis represents the number of seizures per month.
Manish Jain, PhD, MBA retweeted
Dreadds work in humans nejm.org/doi/full/10.1056/NE…
Three people with epilepsy resistant to drug treatment saw the number of seizures they had per month fall by more than 90%, after gene-laden viruses were infused directly into their brains
go.nature.com/3WrLS8G
Manish Jain, PhD, MBA retweeted
A major milestone for Chemogenetics. DREADD technology demonstrates therapeutic efficacy in humans.
A new study published today in NEJM demonstrates preliminary safety and therapeutic benefit from DREADD-based chemogenetic treatment of refractory epilepsy, marking an extraordinary milestone for neuroscience and precision medicine.
nejm.org/doi/full/10.1056/NE…
The approach combines targeted AAV gene delivery at the epileptogenic locus with very low, subthreshold doses of clozapine to activate engineered DREADD receptors and modulate neuronal activity.
Congratulations to Bryan Roth, whose pioneering discovery of DREADDs made this field possible, and to the investigators of the NEJM study for bringing this technology to patients.
This achievement has a particularly meaningful connection to our work published in Science Magazine in 2017.
science.org/doi/10.1126/scie…
We showed that clozapine, rather than CNO itself, is the active mediator of DREADD activation in vivo and proposed that subthreshold doses of clozapine could be used to activate DREADDs in humans, anticipating a practical path toward clinical translation.
At the time, many in the scientific community viewed these findings primarily as relevant to the design of preclinical DREADD experiments. We saw a much broader opportunity, translating Chemogenetics into human therapeutics. Nearly a decade later, that vision is now becoming a reality.
Our 2017 study was supported by the research funding through the National Institutes of Health (NIH) and The National Institute on Drug Abuse (NIDA), a prime example of how fundamental basic research can ultimately enable transformative clinical applications.
This is an exciting beginning, but larger, well-controlled studies are essential to establish the magnitude and durability of therapeutic benefit and long-term safety.
Chemogenetics is moving beyond an experimental neuroscience tool toward a potentially transformative neuroscience platform. We are only beginning to realize its potential.
Why pharma firms are betting billions on psychedelic drugs despite setbacks nature.com/articles/d41586-0…
50
Manish Jain, PhD, MBA retweeted
☕️ Why does coffee taste bitter?
Research from Dr. Bryan Roth’s lab @zenbrainest reveals how the human bitter taste receptor TAS2R43 recognizes caffeine and other compounds naturally found in roasted and brewed coffee!
dailycoffeenews.com/2026/07/…
Manish Jain, PhD, MBA retweeted
An interesting article, although GoA is the major Gi-like G protein in the brain (1% of total brain protein):
Gi Signaling
Does Not Differentiate Hallucinogenic
from Nonhallucinogenic 5-HT2A Receptor Agonists pubs.acs.org/acncdm/article-…
Manish Jain, PhD, MBA retweeted
Gi Signaling Does Not Differentiate Hallucinogenic from Nonhallucinogenic 5-HT2A Receptor Agonists
pubs.acs.org/acncdm/article/…
Manish Jain, PhD, MBA retweeted
This is huge!! @NIMHDirector will allocate $$$ to fund, essentially, clinical trial networks for #psychedelics and other rapidly-acting psychoactives (#ketamine #mdma )
grants.nih.gov/grants/guide/…
Manish Jain, PhD, MBA retweeted
#hiring #postdoc #jobalert
My lab is seeking a Postdoctoral Research Associate to work on GPCRs pharmacology and drug discovery. Interested candidates can apply:
arizona.csod.com/ux/ats/care…
Manish Jain, PhD, MBA retweeted
🧠 What if we could unlock the therapeutic potential of psychedelics without the hallucinations?
Dr. Bryan Roth’s research @zenbrainest on LSD and serotonin receptors was recently featured in SciShow’s “LSD May Lead to a New Kind of Medicine”!
youtube.com/watch?v=lkMtbeU2…
#hiring #postdoc #jobalert
My lab is seeking a Postdoctoral Research Associate to work on GPCRs pharmacology and drug discovery. Interested candidates can apply:
arizona.csod.com/ux/ats/care…
Manish Jain, PhD, MBA retweeted
An innovator in the field of biomedical investigation, Manish Jain, PhD, has joined #uazmedphx's Department of Translational Neurosciences as a tenure-track assistant professor.
Read about his studies and career accomplishments here: bit.ly/4yQlRhp
Manish Jain, PhD, MBA retweeted
Post here: neuroai.science/p/the-race-t…
Manish Jain, PhD, MBA retweeted
LSD May Lead to a New Kind of Medicine
youtube.com/watch?v=lkMtbeU2…
Manish Jain, PhD, MBA retweeted
A suite of engineered mice for interrogating psychedelic drug actions
#psychedelics
Congrats to Yi-ting, Ariel, Bill, Gavin, Dewran, Pierre and too many others to mention. A yuuge effort and we hope that folks will find these mice useful
nature.com/articles/s41593-0…
Manish Jain, PhD, MBA retweeted
DREADDs Enter Human Trials: China’s Breakthrough Stuns Neuroscientists intelligentliving.co/dreadds… via @IntelligLiving
Manish Jain, PhD, MBA retweeted
A proud scientific parent--congrats to @jainmk6 !
Now with his own lab phoenixmed.arizona.edu/trans…










